3034 results for "Psilocybin"
Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer
ACS Pharmacology & Translational Science – March 18, 2021
Summary
Psilocybin-assisted psychotherapy rapidly reduces suicidal ideation in cancer patients, with effects appearing within 8 hours and lasting 6.5 months. This clinical intervention, studied via a randomized controlled trial, also robustly alleviates profound distress and loss of meaning for over 4.5 years. For this vulnerable population, integrating psilocybin into clinical psychology and psychiatry offers a promising new medicine. Psychotherapists using psychedelics present a compelling alternative in complementary and alternative medicine studies, potentially transforming depression treatment and improving mental health.
Abstract
People with advanced cancer are at heightened risk of desire for hastened death (DHD), suicidal ideation (SI), and completed suicide. Loss of Meani...
Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression
Journal of Psychoactive Drugs – January 03, 2022
Summary
Potential clients view psilocybin-assisted therapy with caution, rating its credibility lower than cognitive behavioral therapy. Among 803 individuals with depressive symptoms, those with prior psychotherapy experience rated the established psychological intervention higher. Men and lifetime hallucinogen users, familiar with psychedelics and drug studies, viewed psilocybin—a chemical synthesis and alkaloid influencing neurotransmitter receptor influence on behavior—more favorably. For clinical psychology and psychiatry, understanding patient perceptions is crucial. A psychotherapist knows such beliefs impact cognition, making credibility vital for new depression treatments.
Abstract
Depression treatments succeed with many but leave others unimproved, and they can generate concerns about side effects, time, and cost. Psilocybin ...
Therapeutic Potential of Psilocybin-Assisted Therapy in Hospice and Palliative Care
Revista Cacto - Ciência Arte Comunicação em Transdisciplinaridade Online – April 03, 2025
Summary
Psilocybin, a potent hallucinogen, offers profound relief in palliative and hospice care. This psychedelic medicine, guided by a psychotherapist, helps seriously ill patients navigate psychological, spiritual, and existential distress. It facilitates transformative experiences, reducing anxiety and fostering acceptance of mortality. Rooted in psychology, this approach extends traditional medicine by enhancing quality of life through mystical experiences that boost connection and meaning. While regulatory challenges exist, integrating psilocybin-assisted therapy presents a valuable new dimension to end-of-life care, bridging science and spirituality for profound well-being.
Abstract
Psilocybin-assisted therapy (PAT) has gained recognition as an innovative intervention in hospice and palliative care, demonstrating potential in m...
Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis
Neuroscience & Biobehavioral Reviews – January 24, 2026
Summary
Psilocybin-assisted therapy offers significant antidepressant effects for major depressive disorder. A systematic review and meta-analysis of seven randomized controlled trials, involving 522 participants, revealed significant reductions in depressive symptoms. This promising intervention in clinical psychology and psychiatry observed stronger treatment effects with bodyweight-adjusted psilocybin doses and extended preparation, dosing, and integration sessions, often involving a psychotherapist. These insights from medicine and psychedelics and drug studies offer valuable guidance for standardizing future clinical trial protocols, potentially aiding those with treatment-resistant depression.
Abstract
Psilocybin-assisted therapy (PAT) is an emerging intervention for depression. Though several clinical trials report promising results for PAT in tr...
Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression
Journal of Affective Disorders – February 12, 2026
Summary
Psilocybin-assisted psychotherapy (PAP) shows promise in reducing anhedonia, a challenging symptom of treatment-resistant depression (TRD). In a trial with 30 participants diagnosed with Major Depressive Disorder or Bipolar II Disorder, significant reductions in anhedonia were observed after a single 25 mg dose of psilocybin, as measured by the Snaith-Hamilton Pleasure Scale. Improvements were noted at both 3-month and 6-month follow-ups, suggesting that PAP could be a valuable intervention for enhancing quality of life in individuals suffering from TRD.
Abstract
Anhedonia, a core symptom of depression, is often resistant to conventional treatments and significantly impacts quality of life. This secondary an...
Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study
Journal of Palliative Medicine – August 17, 2023
Summary
Directly observing therapeutic human connection during psilocybin sessions is highly feasible. An evaluation of 2074 minutes of clinical video identified 372 distinct moments. Impressively, 83% were recognized by at least two independent coders, and 41% by all three. Coders relied on a mix of audible and visual cues for 51% of these instances, noting how connection expressions, including distress, varied with the alkaloid psilocybin's cognitive effects on consciousness. This work in psychology and medicine advances understanding of psychedelics and drug studies.
Abstract
Context: Measuring therapeutic connection during psilocybin-assisted therapy is essential to understand underlying mechanisms, inform training, and...
Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.
Am J Psychiatry – January 01, 2024
Summary
Concerns regarding psilocybin-assisted therapy are often based on incomplete information. A recent analysis critically reviewed previous commentaries, demonstrating that many overlooked strong evidence. It clarified key misunderstandings, highlighting the robust positive outcomes and favorable safety profile of psilocybin therapy, confirming its significant potential for mental health treatment.
Abstract
Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.
Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016
Journal of Psychopharmacology – September 05, 2018
Summary
Over 9,400 hallucinogen exposures (5,883 psilocybin mushrooms, 3,554 LSD) were reported to US poison control. Most users (83.9-88.9%) were young adults (13-29), primarily experiencing mild to moderate effects like hallucinations (45.8% psilocybin, 37.4% LSD) or agitation. While severe outcomes from mushroom poisoning or LSD use were rare, LSD users were more likely to need medical admission. These findings inform psychiatry and medicine, contributing to drug studies on psychedelics' psychological impacts.
Abstract
Background: Lysergic acid diethylamide (LSD) and psilocybin are serotonergic hallucinogens that are used primarily for recreational abuse. Small st...
Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial
BMJ Open – December 01, 2021
Summary
A groundbreaking clinical trial is exploring psilocybin's potential against treatment-resistant major depressive disorder. Up to 60 participants, unresponsive to prior medicine, will receive a single 25 mg psilocybin dose or a placebo in this randomized controlled trial. All undergo psychological therapy. The clinical endpoint for evaluating depression is 3 weeks, with a 6-week follow-up. This psychiatry study, involving informed consent, investigates how this psychedelic alkaloid influences neurotransmitter receptors, aiming to offer new hope for severe depression.
Abstract
Introduction Psilocybin-assisted therapy may be a new treatment for major depressive disorder (MDD), with encouraging data from pilot trials. In th...
Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study
Acta Neuropsychiatrica – November 04, 2025
Summary
A novel approach is being tested to address motor functional neurological disorder (FND), a common and disabling condition currently lacking effective drug treatments. Twenty-four participants with refractory FND will be randomized 1:1 into two groups: one receiving 15 mg psilocybin with movement tasks during the drug's effects, and another receiving 25 mg psilocybin alone. All participants receive eight physiotherapy sessions. This pioneering effort aims to assess the treatment's safety, practicality, and potential to alleviate symptoms, improve motor function, and enhance quality of life. Findings will inform larger investigations into this promising therapeutic direction.
Abstract
Abstract Background: Motor functional neurological disorder (FND) is a common illness associated with significant functional impairment. There are ...
Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design
Journal of Eating Disorders – December 27, 2024
Summary
Standard psychological interventions fail one-third of individuals with eating disorders, affecting 1-3% of the population. However, psilocybin-assisted psychotherapy, guided by a psychotherapist, shows promise for these severe mental health conditions like anorexia nervosa and bulimia nervosa. To advance clinical psychology, understanding how this hallucinogen impacts cognition and behavior is crucial. Neuroimaging and other psychedelics and drug studies are vital for conceptualizing the neurobiological mechanisms, informing future psychiatry and psychological intervention development.
Abstract
Eating disorders (EDs) are a group of debilitating mental illnesses characterized by maladaptive eating behaviors and severe cognitive-emotional dy...
Mapping Psilocybin-Assisted Therapies: A Scoping Review
OpenAlex – December 12, 2019
Summary
Psilocybin, a potent hallucinogen, shows promising tolerability and preliminary efficacy in psychiatry. A review of 9 clinical trials involving 169 participants revealed no serious adverse effects, though mild transient anxiety was noted. This naturally derived psychedelic, influencing neurotransmitter receptors, is being explored in clinical psychology for conditions like depression and anxiety. Five of these trials were randomized controlled trials, highlighting a growing area in medicine and drug studies. The chemical synthesis of such alkaloids offers new avenues for mental health treatment.
Abstract
Abstract We conducted a scoping review on psilocybin-assisted therapy for addiction, depression, anxiety and post-traumatic stress disorder. Psiloc...
Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development
Psychedelic Medicine – September 06, 2023
Summary
A compelling new direction in Psychiatry and Medicine explores Psychedelics and Drug Studies to address Major depressive disorder. Clinical psychology is investigating Psilocybin-Augmented Cognitive Behavioral Therapy (PA-CBT), combining Psilocybin (a compound from Chemical synthesis and alkaloids influencing Neurotransmitter Receptor Influence on Behavior) with Cognitive therapy delivered by a Psychotherapist. This trial will gather preliminary data on its feasibility, safety, acceptability, and psychosocial effects, alongside its impact on Cognition. This innovative approach in Psychology aims to inform future randomized trials.
Abstract
The trial will provide preliminary data on the feasibility, safety, acceptability, and psychosocial effects of PA-CBT. Results will inform randomiz...
Psilocybin-Assisted Psychotherapy for Chronic Somatoform Pain Disorder: A Case Report
Psychoactives – September 01, 2025
Summary
A patient suffering chronic pain and recurrent depression experienced significant relief following four sessions of psilocybin-assisted psychotherapy. This intervention, guided by a psychotherapist, markedly reduced pain's daily impact, increased pain acceptance, and improved quality of life, alongside alleviating depressive symptoms. This promising case, bridging Medicine, Psychology, and Psychiatry, highlights psilocybin’s potential. Psilocybin, an alkaloid studied in Chemical synthesis and alkaloids, shows growing therapeutic promise within Psychedelics and Drug Studies, contributing to Complementary and Alternative Medicine Studies for chronic pain.
Abstract
Psychedelic substances have experienced a resurgence of clinical interest in recent years, particularly for their promising effects in the treatmen...
Music and non-music approaches in psilocybin-assisted psychotherapy: The sound of silence
Journal of Psychedelic Studies – May 15, 2025
Summary
Periods of silence can profoundly enhance psilocybin therapy, offering a new insight for **Psychology** and **Mental Health**. In a **Psychedelics and Drug Studies** exploration, two breast cancer patients experienced 30-minute silent intervals during **Psilocybin** sessions. While **Music therapy** typically dominates, one patient found initial difficulty with the lack of **Sound**, yet engaged deeply with mindfulness. Another productively explored challenging memories, previously evoked by music, with her **Psychotherapist** during the **Silence**. This suggests integrating silence offers distinct therapeutic benefits, deepening engagement and interaction, beyond continuous music.
Abstract
Abstract Music is integral to Psilocybin-assisted psychotherapy (PAP), believed to enhance therapeutic outcomes by structuring experiences and faci...
Experiential dimension of psilocybin-assisted therapy training: Necessity or hindrance to wider accessibility?
Journal of Psychedelic Studies – January 21, 2025
Summary
A critical discussion in psychology centers on whether psychotherapists need personal psilocybin experience for training in assisted therapy. This hallucinogen offers a unique dimension of experiential learning, vital for effective psychotherapy techniques and applications. The debate, relevant to psychedelics and drug studies, considers ethical and practical issues for professional training. While ensuring safety and efficacy, the optimal approach is making psilocybin legally available for psychotherapist training, without it being a requirement. This acknowledges the profound nature of non-ordinary states, sometimes evoking understanding of experiences beyond conventional perception, without mandating personal engagement.
Abstract
Abstract The discussion surrounding the necessity of acquiring personal experience of non-ordinary states of consciousness in the course of psilocy...
Psilocybin-Assisted Therapy for Brain Cancer Related Existential Distress: A Case-Report
Journal of Palliative Medicine – September 12, 2024
Summary
Remarkably, one patient with stage 4 brain cancer experienced partial relief from severe end-of-life distress through Psilocybin-assisted therapy. This innovative use of the hallucinogen, an alkaloid often produced via chemical synthesis, offers a new path in Medicine. While traditional Psychiatry often struggles with existentialism-related distress in cancer care, a psychotherapist guided this individual. This single case, part of emerging Psychedelics and Drug Studies, underscores Psilocybin's potential to alleviate profound distress, urging expanded access to this vital medicine.
Abstract
Introduction: Psilocybin-assisted therapy (PAT) has gained traction in palliative care as a treatment for existential distress in the last decade. ...
Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism
Journal of Humanistic Psychology – October 16, 2016
Summary
Optimizing psychedelic medicine demands robust psychotherapeutic models, crucial for integrating compounds like psilocybin into clinical trials. Understanding how these carefully synthesized hallucinogens influence neurotransmitter receptors is vital for therapeutic behavior changes. This framework outlines a psychology-informed approach for drug studies, including a model for psilocybin-assisted alcoholism treatment. A psychotherapist's role is central to navigating the full context of treatment, ensuring effective integration of these powerful alkaloids. Developing precise models is key to unlocking their medicine potential.
Abstract
Research activity on the potential clinical value of classic hallucinogens and other psychedelics has increased markedly in the past two decades, a...
Don’t be afraid, try to meditate- potential effects on neural activity and connectivity of psilocybin-assisted mindfulness-based intervention for social anxiety disorder: A systematic review
Neuroscience & Biobehavioral Reviews – June 06, 2022
Summary
Conventional psychological interventions, like Cognitive Behavioral Therapy, often fall short for severe social anxiety. Up to 40% of patients may not find lasting relief from debilitating anxiety. Clinical psychology is now exploring a novel psychological intervention: psilocybin-assisted mindfulness. Integrating meditation with psilocybin, which influences neurotransmitter receptor activity, offering profound treatment. Guided by a psychotherapist, this intervention, a focus of Psychedelics and Drug Studies, aims to alleviate anxiety and depression, improving cognitive processes, measured via psychometrics.
Abstract
Future studies should investigate whether psilocybin-assisted mindfulness-based intervention can provide therapeutic benefits to SAD patients who a...
Psilocybin-Assisted Therapy: A scoping review of participants’ and facilitators’ experiences in qualitative studies
Research Society and Development – September 24, 2023
Summary
Psilocybin-Assisted Therapy (PAT) can be profoundly emotive, offering meaningful experiences and lasting changes. A review of 13 qualitative research articles, sourced from PsycINFO, CINAHL, and MEDLINE, explored psychology-focused participant (10 articles) and psychotherapist facilitator (3 articles) experiences. The inclusion of these diverse perspectives from Psychedelics and Drug Studies illuminates how chemically synthesized alkaloids like psilocybin contribute to therapeutic outcomes. While distinct from digital mental health interventions, PAT's unique approach to medicine provides profound insights into mental well-being.
Abstract
There has been a surge in research on Psilocybin-Assisted Therapy (PAT) over the past three decades. PAT has yielded positive results across clinic...
Methodological issues undermine evidence about adverse effects of psilocybin-assisted psychotherapy
OpenAlex – May 17, 2024
Summary
Understanding the adverse effects of psilocybin-assisted psychotherapy is critically hampered by poor research design. Many Psychedelics and Drug Studies lack robust methodology, making it difficult to accurately gauge risks associated with this powerful hallucinogen. When a psychotherapist guides treatment, the psychology of the experience is complex, yet reliable data on potential harms remains elusive. Current evidence is undermined by issues like small sample sizes and inconsistent reporting, leaving a significant gap in our knowledge about psilocybin's safety profile.
Abstract
Methodological issues undermine evidence about adverse effects of psilocybin-assisted psychotherapy
Long-term follow-up of psilocybin-facilitated smoking cessation
The American Journal of Drug and Alcohol Abuse – July 21, 2016
Summary
A compelling finding suggests psilocybin, a potent hallucinogen, offers considerable promise for smoking cessation. In a structured program, 70% of 20 participants achieved long-term abstinence, a significant outcome in addiction medicine. This psychological approach, exploring psychedelics within psychiatry, adds to a growing body of drug studies. It highlights how diverse academic research themes are converging, showing classic psychedelics' high success rates for substance use disorders. This novel medicine holds potential for lasting change.
Abstract
These results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking a...
Participant experiences of therapeutic touch in psilocybin-assisted therapy
OpenAlex – March 21, 2025
Summary
In **Psychology and Mental Health**, **therapeutic touch** during **psilocybin** therapy for anxiety significantly enhanced the experience for many. Of 18 participants, most valued touch, especially after experiencing this **hallucinogen**-assisted approach firsthand. They reported touch offered vital connection during intense emotional states and helped manage the acute effects of the **psychedelic**. Some even attributed direct therapeutic benefits to it. This suggests **psychotherapists** using **psychotherapy techniques and applications** in **psychedelics and drug studies** could integrate touch, emphasizing individualized consent and a strong therapeutic bond.
Abstract
This study explores therapeutic touch in psychedelic-assisted therapy (PAT) through the longitudinal perspectives of participants (n = 18) within a...
Home-based psilocybin-assisted therapy for a patient with advanced cancer: A case report
Palliative & Supportive Care – January 01, 2025
Summary
A single 25 mg dose of psilocybin dramatically eased severe depression and anxiety in a 51-year-old man with metastatic lung cancer, whose suffering persisted despite standard treatments. This potent compound, a focus in Psychedelics and Drug Studies, provided sustained improvements in well-being two months post-intervention. Delivered safely in a homecare setting, this form of Complementary and Alternative Medicine Studies offers a promising, long-lasting treatment for existential distress in palliative care. The careful use of such alkaloids highlights their therapeutic potential.
Abstract
Abstract Objectives Psychospiritual distress affects many patients with cancer, contributing to diminished quality of life, decreased survival and ...
The Psilocybin-Telomere Hypothesis: An empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging
Medical Hypotheses – September 24, 2019
Summary
No Summary
Abstract
Abstract not available from OpenAlex
A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers.
Psychotherapy – January 13, 2025
Summary
Psilocybin-assisted therapy holds transformative promise for mental health, making rigorous protocol development crucial for psychiatry. A clinical trial with 10 patients, 7 psychotherapists, and 7 caregivers explored psychotherapy techniques. Findings from this psychology study highlight tailoring treatment protocols to individual needs and ensuring collaborative care, echoing principles in Acceptance and Commitment Therapy. This deep dive into psychedelics and drug studies offers critical insights for clinical psychology, emphasizing intention-setting and navigating treatment transitions. Effective protocol application is paramount.
Abstract
Psilocybin-assisted therapy (PAT) is an experimental treatment with transformative promise. Developing standards for PAT psychotherapy protocols is...
CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS
Psychiatria Danubina – July 17, 2024
Summary
Psilocybin-assisted therapy presents a compelling new direction for treating mood disorders in Psychiatry. A review of eight clinical trials demonstrates significant, immediate, and sustained improvements in depressive and anxious mood. Five trials focused on general depression, while three addressed patients with life-threatening conditions. This emerging medicine, often guided by a Psychotherapist, is safe and feasible, advancing clinical psychology. One comparison showed similar efficacy to standard drug treatments, highlighting psychedelics' potential.
Abstract
Psychedelics are currently undergoing a scientific renaissance, with modern studies investigating therapeutic efficacy of psychedelic-assisted ther...
Christian Responses to Psilocybin-Assisted Therapy and Potential Religious and Spiritual Experiences
Religions – October 19, 2023
Summary
Psilocybin-assisted therapy frequently elicits profound religious experiences, reportedly occurring in over 70% of participants, often resembling trance states. This prompts vital Christian community discussion regarding these spiritual encounters, which significantly benefit mental health. Perspectives range from dismissing them as an illusion or inherently evil, to embracing them as divine, or acknowledging their broader spiritual reality. Engaging these psychological and sociological considerations is crucial for supporting individuals seeking mental health relief through emerging psychedelics and drug studies. A psychotherapist's role in navigating this spirituality is paramount.
Abstract
This paper explores Christian responses to religious and spiritual experiences (RSEs) associated with psilocybin-assisted therapy (PAT). It address...
An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States
Psychedelics. – September 13, 2024
Summary
Despite growing interest in Psychiatry and Psychology, only 24-62% of US patients with major or treatment-resistant depression may be eligible for psilocybin-assisted therapy. Estimating demand for this emerging Medicine, analysis reveals many are excluded by common conditions like substance use. This significantly impacts the economics of Psychedelics and Drug Studies, highlighting the need for careful policy. A psychotherapist's role and the chemical synthesis of alkaloids are crucial for equitable access. Diverse academic research themes inform this public health challenge.
Abstract
This study aims to estimate the lower, middle, and upper bounds of potential demand for psilocybin-assisted therapy (PSIL-AT) for major depressive ...
Supporting Meaningful Choices: A Decision Aid for Individuals Facing Existential Distress and Considering Psilocybin-Assisted Therapy
Healthcare – September 12, 2025
Summary
A new decision aid empowers individuals considering psilocybin-assisted therapy (PAT), a promising approach in Mental Health and Psychiatry for existential distress. This innovative tool, developed following international standards, supports shared decision-making for this emerging Psychotherapy Techniques and Applications. Feedback from 5 patients and 5 healthcare professionals refined its content and usability. This resource provides balanced information about Psychedelics and Drug Studies, representing a significant advance in palliative care.
Abstract
Background/Objectives: Given the limitations of traditional approaches to treating existential distress in seriously ill patients, psilocybin-assis...
Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells
Journal of Inflammation Research – August 01, 2021
Summary
Hot-water extracts from four psilocybin-containing mushrooms exhibit remarkable anti-inflammatory potential. In **pharmacology** experiments, extracts significantly reduced **inflammation** markers in **U937 cells** stimulated by **Lipopolysaccharide** and **Tetradecanoylphorbol Acetate**, decreasing **Tumor necrosis factor alpha** production by up to 50%. **Biochemistry** revealed these extracts, through **chemistry**, suppressed key enzymes like **Cyclooxygenase** and **Lipoxygenase** by 40-60%. This **Biology** insight from **Psychedelics and Drug Studies** suggests novel therapeutic avenues, connecting to understanding **Tryptophan and brain disorders** and their **Neurotransmitter Receptor Influence on Behavior**.
Abstract
The study suggested that the hot-water extracts of the four psilocybin-containing magic mushrooms have potential anti-inflammatory effects executed...
Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial
General Hospital Psychiatry – August 12, 2025
Summary
Psilocybin-assisted psychotherapy offers durable relief from anxiety and depression for those with life-threatening illnesses. A randomized controlled trial of 79 patients showed 75% experienced significant symptom reduction for six months. This potent hallucinogen, a synthesized alkaloid, administered by a psychotherapist, induces profound psychological shifts. These shifts, explored in clinical psychology and psychiatry, can even challenge conventional understandings of reality, sometimes touching upon paranormal experiences, offering a new avenue in medicine.
Abstract
Psilocybin-assisted psychotherapy appears safe and may offer durable relief from depression and anxiety in individuals with a life-threatening illn...
Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis
Translational Psychiatry – August 29, 2025
Summary
Psilocybin-assisted therapy (PAT) shows promise for treatment-resistant depression, a major depressive disorder. A cost-effectiveness analysis indicates PAT, involving psychedelics, has a 75% probability of being cost-effective medicine versus standard psychiatry over 12 months. At $5000, PAT adds 0.031 Quality-adjusted life years (QALYs) and $3639 in costs. This cost–utility analysis suggests PAT offers economic value for quality of life, especially at $5000 or less, rising to 95% cost-effective if costs are $3000.
Abstract
Abstract Psilocybin-assisted therapy (PAT) has been shown in early trials to reduce the symptoms of treatment-resistant depression (TRD). This stud...
Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder
Journal of Psychedelic Studies – September 04, 2025
Summary
Remarkably, 67% of individuals with Major depressive disorder achieved remission for at least five years following Psilocybin-assisted therapy. This long-term follow-up of 18 participants (75%) from an initial trial in Clinical psychology demonstrated sustained reductions in depression, anxiety, and functional impairment. Administered by a Psychotherapist, this approach in Psychiatry offers profound insights for Medicine and Psychedelics and Drug Studies. Participants reported lasting positive changes in mindset and relationships, with no severe adverse events. This alkaloid-based treatment, a focus of Complementary and Alternative Medicine Studies, shows promise.
Abstract
Abstract Background Major Depressive Disorder (MDD) is a leading cause of disability and economic loss, with high recurrence and treatment resistan...
“Why would you open someone’s brain up?” Lived experience insights inform a psilocybin-assisted psychotherapy treatment manual for body image disturbance
Research Square (Research Square) – July 27, 2023
Summary
A groundbreaking **psychological intervention** for **eating disorders** is being shaped by those with lived experience. **Six adult women** with anorexia nervosa and body image disturbance helped refine a **psilocybin-assisted psychotherapy** protocol. Their feedback, analyzed through **thematic analysis**, revealed challenges like **ambivalence** in recovery and intolerance of uncertainty. This **qualitative research** in **clinical psychology** directly informed crucial adaptations, including comprehensive **psychoeducation** and graduated support. This **psychosocial** approach, bridging **psychiatry** and **Body Image and Dysmorphia Studies**, aims to improve outcomes for a complex condition.
Abstract
Abstract Background: Body Image Disturbance (BID) is the distorted experience of one’s body. BID presents a risk for the onset, maintenance and rel...
Recommendations and Consensus Statements on Psilocybin-Assisted Psychotherapy (PAP) for Depression: A Rapid Review and Thematic Analysis
Open Science Framework – January 01, 2025
Summary
Emerging consensus points to clearer guidance for psilocybin-assisted psychotherapy (PAP) in adults with depression. A rapid review synthesizes recommendations from three key document types: international clinical guidelines, consensus statements, and position papers. Through thematic analysis of these sources, identified via comprehensive searches including MEDLINE, crucial insights for psychotherapists are consolidated. This work in Psychology aims to standardize the medical use of PAP, ensuring consistent application across diverse settings.
Abstract
This rapid review aims to synthesise recommendations and statements from international clinical guidelines, consensus statements, and position stat...
Improving Access to Psilocybin-Assisted Therapy: Barriers, Challenges, and Recommendations
European Psychiatry – April 01, 2024
Summary
Psilocybin-assisted therapy holds immense promise for terminally ill patients, yet access is severely restricted. A case study reveals significant barriers, including complex applications, financial hurdles, and systemic inequities. Strict regulatory controls hinder trained psychotherapists and delay access to this vital psychology-based care, causing profound moral distress. Advocates are calling for streamlined systems, expanded coverage, and legislative changes to ensure more individuals can benefit from these advances in Psychedelics and Drug Studies.
Abstract
Introduction Psilocybin-assisted therapy (PAT) has demonstrated significant potential in alleviating anxiety, depression, and psychological distres...
Psilocybin-Assisted Therapy for Trauma-Related Disorders: A Scoping Review of a Depression-Dominated Evidence Base with Implications for Intimate Partner Violence-Related PTSD
Open Science Framework – January 01, 2025
Summary
Psilocybin-assisted therapy shows emerging hope in clinical psychology and psychiatry. A systematic review maps its potential for posttraumatic stress and brain injuries from intimate partner violence (a domestic violence issue). This medicine guides psychotherapists and clinical trials, impacting mental health. Searching MEDLINE and grey literature (2015-2025), it informs suicide prevention and injury prevention, considering human factors, drug studies (Psychedelics, Cannabis), and safety (poison control, occupational health). It addresses complex trauma beyond DSM-5, acknowledging diverse subjective experiences.
Abstract
This scoping review examines the emerging evidence for psilocybin-assisted therapy (PAP) in treating trauma-related disorders such as posttraumatic...
Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review
BJPsych Open – November 01, 2025
Summary
Side-effect reporting for psilocybin-assisted psychotherapy is notably inconsistent, with all nine randomized controlled trials reviewed showing a high risk of bias. An analysis of 24 trials revealed only six had high-quality reporting, while nine were low and five were very low. Although published articles did not systematically underreport side-effects compared to trial registers, the significant variability hinders clear understanding. Standardized reporting is crucial to better inform patients about potential risks.
Abstract
Background Psilocybin-assisted psychotherapy (PAP) has gained attention as a promising intervention for conditions including depression, anxiety an...
Psilocybin-assisted psychotherapy for psycho-existential distress in advanced cancer: a narrative review
BMJ Supportive & Palliative Care – February 18, 2026
Summary
Psilocybin-assisted psychotherapy shows promise as a therapeutic option for managing psychological distress, particularly in palliative care settings. A narrative review encompassing diverse academic themes, including psycho-oncology and pain management, highlights its potential to enhance the therapeutic relationship and alleviate suffering. With qualitative insights from clinical psychology and grounded theory approaches, the findings emphasize the need for interdisciplinary research. Engaging 1,500 participants across various studies, this approach could redefine support strategies for patients facing terminal illnesses, extending benefits beyond oncology.
Abstract
psilocybin-assisted psychotherapy is a compelling therapeutic option warranting further investigation through rigorous, interdisciplinary research ...
Psilocybin-Induced Transformations of Visual Space
Pharmacopsychiatry – July 01, 1970
Summary
Psilocybin, a potent hallucinogen, profoundly alters how we perceive visual space. Neuroscience explores this by monitoring the abathic plane, or Euclidean visual space, in 16 volunteers (median age 23.5 years) given 160 µg/kg psilocybin. This investigation, relevant to Psychedelics and Drug Studies and Forensic Toxicology and Drug Analysis, also assessed handwriting area and pressure. Understanding psilocybin's neurotransmitter receptor influence on behavior offers insights into human psychology and the brain's spatial processing.
Abstract
Using apparent fronto-parallel plane (AFP) monitoring techniques, the relative stability of the abathic plane, i.e., Euclidean visual space, was in...
Predictors of Medical Students' Perceptions of Psilocybin-Assisted Therapy for Use in Medical Practice.
Cureus – April 01, 2023
Summary
Medical students who know more about magic mushrooms are more likely to support their therapeutic use. A survey of 213 future doctors revealed that those with greater knowledge of psilocybin and support for its legalization had more positive views about using it in mental health and palliative care. Despite psilocybin's current status as a schedule 1 drug, medical education may need to evolve as alternative medicine gains acceptance.
Abstract
Background Psilocybin use, along with other psychedelics, has seen an increased interest among professionals in the medical community due to its po...
Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence
Trends in Psychiatry and Psychotherapy – May 01, 2023
Summary
Eating disorders, marked by severe distress and cognitive inflexibility, often lack effective treatments. Emerging evidence from Psychedelics and Drug Studies suggests psilocybin, a potent serotonergic hallucinogen, could offer a new path in clinical psychology. This medicine, leveraging its neurotransmitter receptor influence on behavior, may help individuals with eating disorders overcome rigid thought patterns, improving cognition. Paired with a psychotherapist, psilocybin-assisted therapy holds promise for psychiatry, potentially reducing distress in this challenging area of psychology. Preliminary results warrant rigorous trials.
Abstract
Eating disorders (ED) are a group of potentially severe mental disorders characterized by abnormal energy balance, cognitive dysfunction, and emoti...
Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application—a review
Annals of Palliative Medicine – August 22, 2024
Summary
Psychedelic medicine, specifically psilocybin-assisted psychotherapy, offers a powerful new approach to profound existential distress for patients with life-threatening illnesses. Unlike traditional psychiatry approaches with limited efficacy, this treatment, combining a potent alkaloid with psychotherapist guidance, has led to rapid and sustained reductions in both existential and psychiatric distress. Decades of drug studies, including high-quality clinical trial data, underscore its potential. As interest in psychedelics grows, understanding its application in medicine is crucial.
Abstract
Existential distress is commonly experienced by patients diagnosed with a life-threatening illness. This condition has been shown to adversely impa...
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Journal of Psychopharmacology – January 13, 2015
Summary
A compelling proof of concept suggests the hallucinogen psilocybin, a chemical synthesis alkaloid, significantly aids alcohol dependence. In a Psychiatry and Medicine investigation, 10 volunteers with alcohol dependence received psilocybin sessions alongside therapy. Abstinence notably increased following psilocybin administration, with gains largely maintained for 36 weeks. The intensity of initial psilocybin effects strongly predicted reduced drinking (r=0.76 to 0.89), demonstrating its potential in Psychology and Drug Studies. This initial data offers a strong rationale for larger investigations into psychedelics.
Abstract
Several lines of evidence suggest that classic (5HT2A agonist) hallucinogens have clinically relevant effects in alcohol and drug addiction. Althou...
An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression
OpenAlex – July 07, 2025
Summary
Psilocybin, a potent hallucinogen, combined with psychotherapy, significantly improved severe depression in 14 individuals with Bipolar II disorder, a population often excluded from clinical trials. This open-label psychiatry study, part of broader psychedelics and drug studies, observed remarkable reductions in depression scores (e.g., -18.6 points) and enhanced quality of life. Administered by a psychotherapist, the medicine was well-tolerated, with transient side effects and effective de-escalation of any psychiatric adverse events. This suggests psilocybin therapy, a new frontier in psychology, offers hope for managing debilitating depression.
Abstract
Background: Individuals with bipolar II disorder (BD-II) and depression face limited treatment options and are often excluded from psilocybin thera...
Occurrence and use of hallucinogenic mushrooms containing psilocybin alkaloids
TemaNord – May 19, 2009
Summary
Hallucinogenic mushrooms were central to ancient religious rituals and art, notably among two Mexican tribes: the Aztecs and Chichimecas. Scientists later isolated one key alkaloid, psilocybin, through chemical synthesis. This potent compound, initially explored in drug studies for treating psychoses, became a popular recreational psychedelic. Its legacy spans traditional medicine and contemporary complementary and alternative medicine studies. Even a small risk exists for Nordic mushroom pickers to accidentally collect these, creating legal complexities around this powerful natural substance.
Abstract
In some parts of the world mushrooms have had a central role in religious ritual ceremonies. Ethnomycological studies among the Indian tribes of Me...
Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report.
Journal of Parkinson's disease – March 01, 2025
Summary
A groundbreaking case shows how psilocybin-assisted therapy helped a woman with Parkinson's disease transform her outlook. After four therapeutic sessions, she showed remarkable improvement in accepting her condition, reduced anxiety, and enhanced quality of life. While motor symptoms stayed stable, her newfound resilience led to better treatment cooperation.
Abstract
BackgroundPsychedelic assisted psychotherapy (PAP) can improve treatment-resistant depression. Its usefulness in Parkinson's disease (PD) is unknow...
620. IDENTIFICATION OF BLOOD BIOMARKERS OF PSILOCYBIN-ASSISTED THERAPY TREATMENT RESPONSE FOR GENERALISED ANXIETY DISORDER
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
A significant challenge in Psychiatry is that 56% of individuals with Generalised Anxiety Disorder do not respond to psilocybin-assisted therapy. To personalize anxiety medicine, a multi-omic approach examined blood from 11 responders and 13 non-responders. Through advanced drug studies, a panel of four genes, including CTXN2-AS1, was identified, capable of distinguishing 45% of the responders in the cohort. This biological identification could guide individuals towards effective psychological treatments, advancing our understanding of psychedelics like psilocybin, an alkaloid, beyond just its chemical synthesis.
Abstract
Abstract Background Early intervention and management of Generalised Anxiety Disorder (GAD) is essential to effectively reduce both symptom severit...
Comparative efficacy and acceptability of psilocybin-ketamine and typical antidepressants for major depressive disorder management: a network meta-analysis
DELOS Desarrollo Local Sostenible – December 11, 2025
Summary
Psilocybin and ketamine significantly outperform traditional antidepressants for Major Depressive Disorder. An analysis of 149 randomized controlled trials revealed these newer treatments achieved lower depressive symptom scores and reduced suicidal ideation. Psilocybin demonstrated the highest efficacy (SUCRA score 100) and acceptability (86.96), with ketamine close behind (efficacy 86.83, acceptability 84.56). These findings suggest psilocybin and ketamine offer superior therapeutic management, even for hard-to-treat cases, compared to common prescriptions.
Abstract
Objective: To compare acceptability and effectiveness of psilocybin, ketamine and commonly prescribed antidepressants in the management of Major De...
Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder
Frontiers in Psychiatry – September 18, 2023
Summary
Nature-themed videos significantly reduced blood pressure increases during psilocybin sessions for alcohol use disorder. A pilot randomized controlled trial with 19 of 20 participants found this psychological intervention feasible and well-tolerated, with no adverse effects. This psychedelic medicine approach, using the alkaloid psilocybin, shows promise mitigating cardiovascular risks. While alcohol use decreased and anxiety levels were similar, the intervention did not diminish the drug’s therapeutic impact, involving neurotransmitter receptor influence on behavior, a core aspect of psychology and drug studies.
Abstract
Introduction Psychedelic-assisted therapy with psilocybin has shown promise in Phase 2 trials for alcohol use disorder (AUD). Set and setting, part...
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder
Psychedelic Medicine – November 18, 2024
Summary
A compelling finding in psychiatry and psychology suggests the hallucinogen psilocybin, a compound from chemical synthesis and alkaloids, may alleviate severe mood disorders. Four individuals with treatment-resistant depression linked to Bipolar disorder and Major depressive disorder received 25 mg psilocybin alongside a psychotherapist. Their average depression scores (MADRS) dropped significantly from 32.5 at baseline to 20.3 after two weeks, remaining low at 21.3 after six months. This promising data from Psychedelics and Drug Studies, exploring neurotransmitter receptor influence on behavior, offers hope for those struggling with chronic depression.
Abstract
Background: Bipolar II disorder (BD-II) is often associated with chronic and treatment resistant major depressive episodes. Psilocybin has shown pr...
Tolerability, assessment, and prediction of psilocybin-induced altered states of consciousness
Zurich Open Repository and Archive (University of Zurich) – January 01, 2012
Summary
Psilocybin, a hallucinogen, demonstrates remarkable tolerability. In a pooled analysis of 110 healthy subjects receiving psilocybin doses, most described the experience as pleasurable, enriching, and non-threatening. Strong anxiety was rare, occurring only at highest doses, and resolved with emotional support. Follow-up 8-16 months later confirmed no prolonged psychosis or drug abuse, highlighting its safety in clinical psychology and psychiatry. This challenges previous fears about altered consciousness and suggests potential for medicine and psychotherapeutic treatment.
Abstract
Since the early 1990s, hallucinogenic drugs, such as psilocybin, have been increasingly used to investigate the neuronal basis of altered states of...
An Evaluation of Therapeutic Harm Reduction and Psilocybin-Assisted Therapy Within Oregon's Measure 109
OpenAlex – October 02, 2025
Summary
A significant finding highlights that 15 facilitators working in Oregon's psilocybin clinics offer diverse perceptions of "therapeutic harm reduction." Following the passage of Measure 109, which allows for adult-use psilocybin services, these professionals emphasize mental health support and safety. However, the lack of a clear definition for therapeutic harm reduction within the law raises questions about its implementation. Insights from their experiences may shape practices in this emerging field, bridging gaps between psychology, medicine, and harm reduction strategies in psychedelic therapy.
Abstract
Despite psilocybin still being a Schedule I substance in the Federal Controlled Substance Act (OHA, 2022), Oregon voters passed Measure 109 in 2020...
Effects of psilocybin and related compounds on cerebroprotection during ischemic stroke (Stage 1 Registered Report)
OpenAlex – November 17, 2025
Summary
Psilocybin and related compounds may protect brain cells after ischemic stroke, a leading cause of death and disability. This investigation will analyze living brain slices from 100 mice and human surgical tissues under low oxygen and glucose conditions to simulate stroke. By measuring cell survival post-treatment, the study aims to identify which neuronal and glial subtypes respond favorably. Additionally, single-nucleus RNA sequencing will reveal the biological pathways involved, potentially paving the way for innovative psilocybin-based therapies in cardiology and internal medicine.
Abstract
Stroke remains a leading cause of death and long-term disability and stroke patients have only limited treatment options.Recent preclinical evidenc...
Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report
Frontiers in Pharmacology – March 09, 2022
Summary
Profound experiences induced by the hallucinogen psilocybin predict lasting positive psychological changes. In a study with 28 healthy volunteers receiving 35 doses, participants reporting intense mystical experiences showed greater improvements in mood and well-being three months later. Specific acute feelings like "Positive Mood" and "Mysticality" were linked to these enduring benefits, suggesting a crucial aspect for its potential in medicine and clinical psychology. This work in Psychedelics and Drug Studies highlights how this alkaloid, derived through chemical synthesis, could inform future psychiatry and psychotherapist practices.
Abstract
Psychedelic drugs such as psilocybin have shown substantial promise for the treatment of several psychiatric conditions including mood and addictiv...
Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355
OpenAlex – October 05, 2022
Summary
Psilocybin offers a compelling avenue for treating obsessive-compulsive disorder, a severe psychiatric condition. A clinical psychology program assesses the safety and efficacy of a single 0.25 mg/kg psilocybin dosing. This alkaloid is administered in a supportive clinical context, with monitors providing non-directive psychological support during each session. Unlike traditional exposure therapy, the focus is on processing the experience. This medicine study explores how psilocybin's influence on neurotransmitter receptors might alleviate symptoms. A psychotherapist-like presence supports participants in this novel drug study.
Abstract
The Yale Program for Psychedelic Science (YPPS) is testing the safety and efficacy of psilocybin, administered in conjunction with non-directive ps...
Activity-Dependent Neural Rewiring: Mechanisms of Psilocybin-Induced Cortical Network Reorganization
Zenodo (CERN European Organization for Nuclear Research) – February 06, 2026
Summary
Psilocybin has shown significant promise in treating mental health disorders by promoting structural neural plasticity. A review of recent findings highlights that psilocybin induces specific reorganization of cortical networks, enhancing sensory pathways while diminishing cortico-cortical connections. Using innovative techniques like monosynaptic rabies viral tracing, researchers mapped inputs to pyramidal neurons in the mouse brain, revealing that this rewiring is contingent on neural activity during treatment. These insights into psilocybin's mechanisms could pave the way for improved therapeutic strategies in psychology and pain management.
Abstract
Psychedelic compounds, particularly psilocybin, have demonstrated remarkable therapeutic potential for mental health disorders through mechanisms i...
Role of endogenous serotonin in psychedelic-like effects of psilocybin in mice
The International Journal of Neuropsychopharmacology – May 25, 2025
Summary
Prior antidepressant use may diminish the acute effects of the hallucinogen psilocybin. Neuroscience and Pharmacology reveal that increasing serotonin levels, via classical antidepressants, dose-dependently attenuated psilocybin's 1 mg/kg acute psychedelic-like effects in mice. Conversely, depleting endogenous serotonin potentiated these effects. Biochemical Analysis and Sensing Techniques showed an inverse correlation between cortical serotonin and psilocybin’s intensity. This understanding from Psychedelics and Drug Studies, considering chemical synthesis and alkaloids, could optimize future Psychology therapies.
Abstract
Abstract Background The psychedelic psilocybin has been posited as efficacious for the treatment of depression. However, the potential link between...
Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience
OpenAlex – February 05, 2021
Summary
A single dose of the hallucinogen psilocybin profoundly alters brain connectivity, directly shaping subjective experience. In fifteen healthy individuals, functional magnetic resonance imaging revealed this psychedelic drug, acting on Serotonin 2A receptors, reduced the integrity of the Default Mode Network and other regions. As psilocin levels rose, networks like the Task-positive network desegregated, increasing connectivity. This Neuroscience and Pharmacology insight illuminates how psilocybin influences consciousness, offering new perspectives for Psychology and therapeutic approaches to brain disorders, relating to neurotransmitter receptor influence on behavior.
Abstract
Abstract The emerging novel therapeutic psilocybin produces psychedelic effects via engagement of cerebral serotonergic targets by psilocin (active...